Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corporation (Nasdaq: OPRX) regularly issues news and updates about its healthcare technology platform, partnerships, and financial performance. Company press releases describe OptimizeRx as a healthcare technology company that helps life science brands reach and engage healthcare professionals (HCPs) and patients through AI-driven tools, point-of-care integrations, and proprietary audience data.
News items for OptimizeRx often cover collaborations with other data and media companies, such as integrations that connect its patented Micro-Neighborhood® audience data with external identity graphs or out-of-home advertising networks. These announcements explain how the company’s privacy-safe, deterministic audience cohorts are used to support omnichannel and direct-to-consumer campaigns, improve audience quality, and reduce audience loss during onboarding and activation.
Investors and observers will also find earnings releases and guidance updates among OptimizeRx news. These releases include discussions of revenue trends, profitability metrics, key performance indicators related to top pharmaceutical manufacturers, and commentary from management about the company’s progress toward its strategic objectives. Conference call announcements and investor conference participation are also common topics, providing details on how to access management’s discussions of quarterly and annual results.
Additional news highlights may include expansions of the company’s in-workflow point-of-care network through new or renewed agreements with electronic health record (EHR) vendors, e-prescribing platforms, and health systems access partners. Leadership updates and organizational changes are reported through current reports and associated press releases, outlining adjustments in executive roles and governance. For anyone following OPRX, this news page serves as a central source for official company communications on partnerships, technology developments, financial results, and corporate governance.
OptimizeRx Corp. (Nasdaq: OPRX) has been invited to the Bank of America 4th Annual HCIT and Digital Health Symposium on December 9-10, 2020. CEO William Febbo will speak on the panel discussing "Trends in Tech-Enabled Rx Supply Chain." The event will include healthcare-focused Bank of America clients and executives from various sectors, including digital health and private equity. OptimizeRx offers digital health solutions linking healthcare providers and patients, helping improve medication affordability and adherence.
OptimizeRx announces a partnership with Komodo Health to integrate its Healthcare Map with OptimizeRx's digital health platform. This collaboration aims to enhance real-world evidence delivery to healthcare providers, expanding OptimizeRx's audience and improving care through actionable insights. As the COVID-19 pandemic has changed care delivery, the partnership focuses on addressing gaps in timely information for healthcare providers. OptimizeRx aims to leverage this integration to bolster patient and physician experiences, ultimately improving treatment outcomes.
OptimizeRx Corp. (Nasdaq: OPRX) has launched an innovative enhancement to its digital health platform that utilizes real-world data (RWD) and machine learning to deliver therapeutic support directly to clinicians at critical patient care moments. This unprecedented approach aims to improve communication and data accessibility in healthcare, potentially enhancing patient outcomes, especially in complex cases like oncology. OptimizeRx emphasizes the importance of actionable data for effective treatment decisions and aims to improve healthcare systems through its AI-driven capabilities.
OptimizeRx Corp. (Nasdaq: OPRX) has reported a remarkable 217% revenue growth from 2016 to 2019, attributed to its expanding digital health platform. The company earned the 432nd spot on Deloitte’s Technology Fast 500, recognizing fast-growing tech companies in North America. CEO William Febbo emphasized the significance of their digital health solutions and a dedicated team. The recent record revenue of $10.5 million for Q3 2020, reflecting a 110% increase year-over-year, signals continued strong performance in a growing market.
OptimizeRx Corp. (Nasdaq: OPRX) has partnered with Fierce Life Sciences to host a virtual event, Innovate4Outcomes, on December 3, 2020. The event aims to address key healthcare challenges exacerbated by COVID-19, promoting collaboration among industry leaders to enhance patient outcomes. Discussions will focus on supporting providers, the role of clinicians in digital strategies, adoption of patient support programs, and leveraging social media for patient engagement. Attendance is limited to 100 participants.
OptimizeRx Corp. (Nasdaq: OPRX) has appointed Angelo Campano as senior vice president and principal of agency channels to enhance partnerships with healthcare advertising agencies. With over 15 years of experience, Campano aims to drive strategic growth at OptimizeRx, including implementing point-of-care engagement programs for targeted patient populations. His background includes significant achievements in electronic health record (EHR) workflows and marketing at Ogilvy Health. The company's digital health platform connects life sciences with healthcare providers, facilitating medication affordability for patients.
OptimizeRx Corp. (Nasdaq: OPRX) reported significant financial growth for Q3 2020, with revenue increasing by 110% to $10.5 million and gross profit up 99% to $6.0 million. Non-GAAP net income was $1.1 million or $0.07 per share. The cash balance was $12.0 million, down from $14.1 million due to higher working capital investments. The company closed additional enterprise deals worth $3.6 million and expanded its digital health network through partnerships with Higi and Epion Health. Despite a GAAP net loss of $0.3 million, management remains optimistic about future growth.
OptimizeRx Corp. (Nasdaq: OPRX) will host a conference call on November 9, 2020, to discuss its Q3 2020 results, expecting record revenue exceeding $10 million, a 100% increase from the previous year. The call will also cover the growth driven by enterprise deals and the value of its Digital Health Platform. Financial results will be released prior to the call, with a question-and-answer segment to follow. Interested parties can join via toll-free and international dial-in numbers. A replay will be available until November 30, 2020.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, will participate in two investor conferences in November 2020. The events are the Roth Technology Virtual Conference on November 11 and the Stifel Midwest One-on-One Growth Conference on November 12. Management will engage in one-on-one meetings with institutional investors to discuss the company’s anticipated record revenue exceeding $10 million for Q3 2020, representing over 100% year-over-year growth. This growth stems from strong enterprise deals and programs enhancing value for life science customers.
OptimizeRx Corp. (Nasdaq: OPRX) reported impressive preliminary revenue for Q3 2020, exceeding $10 million, a 100% year-over-year increase. The company anticipates positive non-GAAP net income for the quarter due to organic growth driven by enterprise deals and tactical programs. The revenue for the first nine months surged over 53% to $26.4 million. The CEO noted a strategic focus on expanding physician and patient reach, attributing growth to increased enterprise agreements. Full Q3 results will be disclosed in early November.